Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer

BackgroundDiagnosis of pancreatic cancer (PC) by using sensitive and specific biomarkers is considered necessary. MiRNAs are master regulators of gene expression and several biological processes, and they are dysregulated in various cancers, where they play a vital role in either cancer progression or suppression. So, this study was designed to investigate the role of plasma miR-22-3p, miR-642b-3p and miR-885-5p expression as possible diagnostic markers in PC patients as compared to serum CA19-9. In addition, the correlation of those miRNAs and CA19-9 with clinical characteristics of PC patients was analyzed.MethodsThe expression levels of selected miRNAs and serum CA19-9 concentration were determined for 35 patients with PDAC and 15 healthy controls by quantitative real-time RT-PCR and electro-chemiluminescence immune assay, respectively. The sensitivities of miRNAs as biomarkers of PC were evaluated and compared with CA19-9 using a receiver operating characteristic analysis.ResultsThe levels of three miRNAs (miR-22-3p, miR-642b-3p and miR-885-5p) and CA19-9 were significantly higher in PC patients, even those with early-stage disease (IB and IIB), than in healthy control. Both miRNAs and CA19-9 were associated with tumor stage. The high sensitivities of the three selected miRNAs and CA19-9 were observed.ConclusionThe measurement of miR-22-3p, miR-642b-3p and miR-885-5p may prove to have clinical utility in diagnosis of PC. Those miRNAs are ideal early biomarkers for PC diagnosis. So, they can effectively be used with serum CA19-9 for PC screening in early tumor stage.

[1]  S Badve,et al.  Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22 , 2011, Oncogene.

[2]  Jong Y. Park,et al.  MicroRNAs in pancreatic ductal adenocarcinoma. , 2011, World journal of gastroenterology.

[3]  George A Calin,et al.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. , 2008, Blood.

[4]  Q. Yao,et al.  Roles and Mechanisms of MicroRNAs in Pancreatic Cancer , 2011, World Journal of Surgery.

[5]  C. Dani,et al.  Small RNA sequencing reveals miR-642a-3p as a novel adipocyte-specific microRNA and miR-30 as a key regulator of human adipogenesis , 2011, Genome Biology.

[6]  M. Fakih,et al.  Leukemoid reaction in pancreatic cancer: a case report and review of the literature. , 2006, JOP : Journal of the pancreas.

[7]  Richard T. Jaspers,et al.  Attenuated Increase in Maximal Force of Rat Medial Gastrocnemius Muscle after Concurrent Peak Power and Endurance Training , 2013, BioMed research international.

[8]  S. Batra,et al.  Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. , 2015, Advanced drug delivery reviews.

[9]  R. Hruban,et al.  MicroRNA Array Analysis Finds Elevated Serum miR-1290 Accurately Distinguishes Patients with Low-Stage Pancreatic Cancer from Healthy and Disease Controls , 2013, Clinical Cancer Research.

[10]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[11]  Hongliang Liu,et al.  A functional variant at the miR‐885‐5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  N. Tanaka,et al.  Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer , 2014, International journal of oncology.

[13]  T. Jiang,et al.  Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme , 2011, Brain Research.

[14]  R. Guimbaud,et al.  MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. , 2014, World journal of gastroenterology.

[15]  G. Weiss,et al.  MicroRNAs and cancer: past, present, and potential future , 2008, Molecular Cancer Therapeutics.

[16]  Arnab Ghosh,et al.  The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease Progression , 2016, International journal of molecular sciences.

[17]  A. Wellstein,et al.  Circulating DNA and Micro-RNA in Patients with Pancreatic Cancer , 2015, Pancreatic disorders & therapy.

[18]  L. Benesova,et al.  MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Diagnosis and Prognosis , 2015, Gastroenterology research and practice.

[19]  Y. Tu,et al.  Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis , 2013, Diagnostic Pathology.

[20]  Peng-jun Zhang,et al.  Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies , 2010, Clinical science.

[21]  F. Westermann,et al.  MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival , 2011, Cell Death and Differentiation.

[22]  T. Ørntoft,et al.  Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. , 1999, Clinical chemistry.

[23]  Hong Yu,et al.  Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker. , 2014, International journal of clinical and experimental medicine.

[24]  H. Frucht,et al.  Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. , 2014, World journal of gastroenterology.

[25]  R. Strair,et al.  Differentiation-associated miR-22 represses Max expression and inhibits cell cycle progression. , 2010, Biochemical and biophysical research communications.

[26]  Eva E. Rufino-Palomares,et al.  MicroRNAs as Oncogenes and Tumor Suppressors , 2013 .

[27]  De-cai Yu,et al.  Circulating MicroRNAs: Potential Biomarkers for Cancer , 2011, International journal of molecular sciences.

[28]  Massimo Negrini,et al.  MicroRNAs in human cancer: from research to therapy , 2007, Journal of Cell Science.

[29]  D. Jin,et al.  Combined Serum CA19-9 and miR-27a-3p in Peripheral Blood Mononuclear Cells to Diagnose Pancreatic Cancer , 2013, Cancer Prevention Research.

[30]  S. Rai,et al.  MicroRNA signature of cisplatin resistant vs . cisplatin sensitive ovarian cancer cell lines , 2011 .

[31]  C. Müller,et al.  The Combined Elevation of Tumor Markers CA 19-9 and CA 125 in Liver Disease Patients Is Highly Specific for Severe Liver Fibrosis , 2006, Digestive Diseases and Sciences.

[32]  A. Ko.  Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Mahato,et al.  miRNAs in pancreatic cancer: therapeutic potential, delivery challenges and strategies. , 2015, Advanced drug delivery reviews.

[34]  Nathan S. Abell,et al.  A Myc–microRNA network promotes exit from quiescence by suppressing the interferon response and cell-cycle arrest genes , 2013, Nucleic acids research.

[35]  Kyung Mi Lim,et al.  Arctiin blocks hydrogen peroxide-induced senescence and cell death though microRNA expression changes in human dermal papilla cells , 2014, Biological Research.

[36]  Chen Wu,et al.  An estrogen receptor α suppressor, microRNA‐22, is downregulated in estrogen receptor α‐positive human breast cancer cell lines and clinical samples , 2010, The FEBS journal.

[37]  Cicek Gercel-Taylor,et al.  MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. , 2008, Gynecologic oncology.

[38]  Stefano Ferrero,et al.  Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma , 2015, PloS one.

[39]  G. Calin,et al.  Clinical relevance of circulating cell-free microRNAs in cancer , 2014, Nature Reviews Clinical Oncology.

[40]  Y. Gong,et al.  Combination of plasma microRNAs with serum CA19‐9 for early detection of pancreatic cancer , 2012, International journal of cancer.

[41]  G. A. Ganepola,et al.  Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. , 2014, World journal of gastrointestinal oncology.

[42]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Yamakuchi,et al.  MicroRNA-22 Regulates Hypoxia Signaling in Colon Cancer Cells , 2011, PloS one.

[44]  Wen Chen,et al.  Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. , 2015, World journal of gastroenterology.

[45]  Jianjun Chen,et al.  MicroRNAs in cancer biology and therapy: Current status and perspectives , 2014, Genes & diseases.

[46]  Ju-hui Qiu,et al.  Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3 , 2012, Journal of Cancer Research and Clinical Oncology.

[47]  Anton J. Enright,et al.  Targeted Deletion of MicroRNA-22 Promotes Stress-Induced Cardiac Dilation and Contractile Dysfunction , 2012, Circulation.

[48]  Z. Dong.  Hepatic diseases related peripheral blood RNAs variation and their clinical significance , 2013 .

[49]  G. Malaguarnera,et al.  Carbohydrate 19.9 Antigen Serum Levels in Liver Disease , 2013, BioMed research international.

[50]  In‐San Kim,et al.  Identification of Motifs for Cell Adhesion within the Repeated Domains of Transforming Growth Factor-β-induced Gene,βig-h3 * , 2000, The Journal of Biological Chemistry.

[51]  S. Rai,et al.  MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines , 2011, Journal of ovarian research.

[52]  Motohiro Kojima,et al.  MicroRNA Markers for the Diagnosis of Pancreatic and Biliary-Tract Cancers , 2015, PloS one.

[53]  C. Yeo,et al.  Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer , 2013, Journal of surgical oncology.

[54]  F. Mansour-Ghanaei,et al.  The Frequency of CA15-3, CA125, CA19-9 in Patients With Hepatitis B and C , 2015 .